Search Results

You are looking at 241 - 250 of 2,710 items for :

  • Refine by Access: All x
Clear All
Full access

Extending Comprehensive Cancer Center Expertise in Clinical Cancer Genetics and Genomics to Diverse Communities: The Power of Partnership

Deborah J. MacDonald, Kathleen R. Blazer, and Jeffrey N. Weitzel

genetics ( Figure 2 ). The CSPPN and CGEP facilitate the integration of genetics services in the community and provide access to a robust program of laboratory and health services research through an institutional review board–approved Hereditary Cancer

Full access

Biomarkers in Colorectal Cancer Screening

Minhhuyen T. Nguyen and David S. Weinberg

in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/79280 ; and 4

Full access

Update on Guidelines for the Prevention of Cancer-Associated Thrombosis

Amro Elshoury, Jordan K. Schaefer, Ming Y. Lim, Deidre P. Skalla, and Michael B. Streiff

patients with cancer will develop thrombosis ( Table 1 ). 4 Cancer-associated thrombosis (CAT), including both venous and arterial events, is the second leading cause of death in patients with cancer. 5 This review summarizes the recently updated NCCN

Full access

Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Ignacio Garrido-Laguna, Jean L. Grem, Sarah E. Hoffe, Joleen Hubbard, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina S. Pedersen, Leonard B. Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Alyse Johnson-Chilla, Kristina M. Gregory, and Lisa A. Gurski

metastatic disease, and survivorship. When reviewing these guidelines, clinicians should be aware of several things. First, these guidelines adhere to the TNM (tumor, node, metastases) staging system (see definitions of TNM in Table 1, available online, in

Full access

Role of Surgery for Locally Advanced and Metastatic Renal Cell Carcinoma

Robert Torrey, Philippe E. Spiess, Sumanta K. Pal, and David Josephson

reviewed some of the larger series examining the capabilities of cross-sectional imaging (CT/MRI) in the preoperative detection of adrenal gland involvement. Although the positive predictive value was found to range between 26% and 93%, most values were 50

Full access

NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023

Featured Updates to the NCCN Guidelines

Therese B. Bevers, Bethany L. Niell, Jennifer L. Baker, Debbie L. Bennett, Ermelinda Bonaccio, Melissa S. Camp, Sona Chikarmane, Emily F. Conant, Mohammad Eghtedari, Meghan R. Flanagan, Jeffrey Hawley, Mark Helvie, Linda Hodgkiss, Tamarya L. Hoyt, Jennifer Ivanovich, Maxine S. Jochelson, Swati Kulkarni, Rachael B. Lancaster, Caitlin Mauer, Jessica Maxwell, Bhavika K. Patel, Mark Pearlman, Liane Philpotts, Donna Plecha, Jennifer K. Plichta, Shadi Shakeri, Mary Lou Smith, Clarie L. Streibert, Roberta M. Strigel, Lusine Tumyan, Nicole S. Winkler, Dulcy E. Wolverton, Mary Anne Bergman, Rashmi Kumar, and Katie Stehman

participation. To participate in this journal CE activity: (1) review the educational content; (2) take the posttest with a 66% minimum passing score and complete the evaluation at https://education.nccn.org/node/92935 ; and (3) view/print certificate

Full access

Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?

Jan Philipp Bewersdorf, Scott F. Huntington, and Amer M. Zeidan

effectiveness specific to these novel agents are missing. This review provides a historical overview of cost-effectiveness analyses in AML and uses recent studies as examples to highlight limitations and future directions. AML Care Costs, Historic

Full access

Nonmelanoma Skin Cancer in Childhood and Young Adult Cancer Survivors Previously Treated With Radiotherapy

Stefanie L. Thorsness, Azael Freites-Martinez, Michael A. Marchetti, Cristian Navarrete-Dechent, Mario E. Lacouture, and Emily S. Tonorezos

recurrence of NMSC in childhood cancer survivors previously treated with RT, with the goal of providing more accurate risk classification. Methods We conducted a retrospective chart review (1994–2017) of childhood and young adult cancer survivors previously

Full access

Targeted Agents: Management of Dermatologic Toxicities

Barbara Burtness

this time. A Glimpse at Ocular Toxicity and EGFR Inhibitors Dr. Burtness briefly reviewed the effect of EGFR inhibitors on the eyes ( Figure 1 ). Among the reported ocular side effects are conjunctivitis, blepharitis, trichomegaly, corneal

Full access

Major Changes in Systemic Therapy for Advanced Melanoma

John A. Thompson

monoclonal antibody directed to the immune checkpoint receptor cytotoxic T-lymphocyte antigen 4 (CTLA4) ipilimumab was approved by the FDA. Dr. Thompson briefly reviewed the long-term survival data with ipilimumab. 3 He added, “We are now seeing a tail in